Interestingly, RAF/MEK inhibition is rather ineffective at killing melanoma cells, as A375 cell viability remains between ~ 70% and ~ 25% under 2D and 3D conditions at the highest concentration of 1 μM Dabrafenib + 100 nM Trametinib (Fig. 2c). The gene discussed is MAP2K7; the disease is melanoma.